EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium

Armelle Duquenne, Nathalie Brison, Ilse Parijs, Angelica Pagliazzi, Machteld Baetens, Bettina Blaumeiser iD, Marie Bruneau, Saskia Bulk, Bert Callewaert, Sandra Coppens, Michelle Deberg, Anne De Leener and 23 more

Prenatal Diagnosis · 2026

DOI: 10.1002/pd.70236 ↗

At a glance

Multizentrische Studie in Prenatal Diagnosis, 2026. Written by Armelle Duquenne and 34 co-authors. Institution: Center for Human Genetics, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. Major MEDLINE topics: Cell-Free Nucleic Acids, Noninvasive Prenatal Testing, Prenatal Diagnosis. 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: KU Leuven.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Prenatal cell‐free DNA screening is widely used to assess the risk of fetal trisomy 21, 18, and 13. Although commercial and laboratory‐developed tests (LDTs) show high accuracy in validation studies, real‐world longitudinal performance data are lacking.

Method

In Belgium, prenatal cell‐free DNA screening is a population screening offered to all pregnant people, regardless of their a priori risk. Over 3 years, all confirmatory diagnostic tests after a positive prenatal cell‐free DNA screening result were recorded along with the technologies used and their outcomes. Positive predictive values (PPVs) for the three common fetal trisomies were calculated per technology.

Results

A total of 1158 diagnostic tests were performed after a positive prenatal cell‐free DNA screening. Of these, 58.5% came from an LDT, 15.7% from VeriSeq (Illumina), 6.6% from Harmony (Roche), 5% from Vanadis (Perkin‐Elmer); for 14.2% the technology could not be traced. PPVs ranged from 92.2% to 65.7% for trisomy 21, from 82.8% to 44.4% for trisomy 18, and from 40% to 18.2% for trisomy 13. Overall, the LDT performed better than the commercial tests.

Conclusion

This study confirms the reported accuracy of commercial tests and LDT, while showing that LDT generally outperforms commercial tests. Despite high specificities across tests, differences in PPVs significantly impact pregnant people and the national health care system.

Subjects

MeSH terms (MEDLINE)

Cell-Free Nucleic AcidsNoninvasive Prenatal TestingPrenatal DiagnosisAdultFemaleHumansPregnancyBelgiumLongitudinal StudiesPredictive Value of TestsTrisomy 13 SyndromeTrisomy 18 Syndrome

Substances

Cell-Free Nucleic Acids

Authors and institutions

  • Center for Human Genetics, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
  • Center for Human Genetics, University Hospital Leuven-KU Leuven, Leuven, Belgium.
  • Center for Medical Genetics, University Hospital Ghent, Ghent, Belgium.
  • Center for Medical Genetics, University and University Hospital Antwerp, Antwerp, Belgium.
  • Center for Human Genetics, University Hospital Erasme-ULB, Brussels, Belgium.
  • Center for Medical Genetics, University Hospital Liège, Liège, Belgium.

ORCID profiles: Bettina Blaumeiser, Björn Menten, Colombine Meunier, Ileen Slegers

Funding

  • KU Leuven

Cite

APA

Duquenne, A., Brison, N., Parijs, I., Pagliazzi, A., Baetens, M., Blaumeiser, B., Bruneau, M., Bulk, S., Callewaert, B., Coppens, S., Deberg, M., Leener, A., Rademaeker, M., Désir, J., Devriendt, K., Fieuw, A., Gatot, J. S., Jamar, M., Janssens, S., …, & Janssens, K. (2026). Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium. Prenatal Diagnosis. https://doi.org/10.1002/pd.70236

Vancouver

Duquenne A, Brison N, Parijs I, Pagliazzi A, Baetens M, Blaumeiser B, et al. Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium. Prenatal Diagnosis. 2026. doi:10.1002/pd.70236

BibTeX
@article{Duquenne2026,
  author = {Duquenne, Armelle and Brison, Nathalie and Parijs, Ilse and Pagliazzi, Angelica and Baetens, Machteld and Blaumeiser, Bettina and Bruneau, Marie and Bulk, Saskia and Callewaert, Bert and Coppens, Sandra and Deberg, Michelle and Leener, Anne De and Rademaeker, Marjan De and Désir, Julie and Devriendt, Koenraad and Fieuw, Annelies and Gatot, Jean-Stéphane and Jamar, Mauricette and Janssens, Sandra and Lannoo, Lore and Marichal, Axel and Menten, Björn and Meunier, Colombine and Pichon, Bruno and Rombout, Sonia and Slegers, Ileen and Sznajer, Yves and Vanakker, Olivier and Van Berkel, Kim and Vancoillie, Leen and Bogaert, Ann Van Den and Vandernoot, Isabelle and Bogaert, Kris Van Den and Vermeesch, Joris R and Janssens, Katrien},
  title = {Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium},
  journal = {Prenatal Diagnosis},
  year = {2026},
  doi = {10.1002/pd.70236}
}
Start for free →